COMMUNIQUÉS West-GlobeNewswire

Syncromune®, Inc. Presents Innovative SYNC-T™ Combination Immunotherapy Approach at Major European Interventional Oncology Conference
29/04/2026
Novel procedure combines image-guided tumor cryolysis with intratumoral immunotherapy infusion, with early clinical findings in metastatic prostate cancer FORT LAUDERDALE, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- [...]
TOMI Environmental Solutions Targets $70 Billion U.S. Drone and Defense Budget with Autonomous SteraMist iHP Decontamination
29/04/2026
Strategic Initiative Focuses on Automated Biological and Chemical Defense for Land, Air, Sea, and Space FREDERICK, Md., April 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a [...]
Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting
29/04/2026
LONDON and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission to save and [...]
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
29/04/2026
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approach GLEN ALLEN, Va., April 29, 2026 ( [...]
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
29/04/2026
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May 2–5, 2026, in Chicago IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE [...]
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
29/04/2026
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra [...]
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting
29/04/2026
Dual-targeted allogeneic CAR-T therapy demonstrates immune-reset mechanism and durable remission in system lupus erythematosus BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology [...]
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
29/04/2026
THE WOODLANDS, TX, April 29, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Codexis to share RNA manufacturing advances at TIDES USA
29/04/2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO [...]
SkinHealth Systems to Report First Quarter 2026 Financial Results on May 7, 2026
29/04/2026
LONG BEACH, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN), a global medical aesthetics company, today announced it will report first quarter 2026 [...]
CMR Surgical Submits 510(k) Application to U.S. FDA to Expand Versius Plus™ into Gynecology
29/04/2026
PRESS RELEASE Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology. This Submission Builds On Extensive Global Clinical Experience in Gynecology and Continues CMR’s U.S. [...]
CorVel Corporation Launches CorVel Connected™, an AI-Powered Claims Intelligence Layer Embedded in CareMC®
29/04/2026
Supporting faster, more consistent end-to-end claim management by embedding decision-support intelligence directly into daily workflows—without replacing human judgment FORT WORTH, Texas, April 29, 2026 (GLOBE NEWSWIRE [...]
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
29/04/2026
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
29/04/2026
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel [...]
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
29/04/2026
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: [...]
DLH to Announce Fiscal 2026 Second Quarter Financial Results
29/04/2026
ATLANTA, April 29, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Laguna Announces FDA Clearance of IND Application for LGNA-100, a Novel γδ T Cell Activator for High-Risk Pediatric Leukemias
29/04/2026
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Laguna Biotherapeutics, Inc. (Laguna), a clinical-stage biotechnology company focused on novel live bacterial therapeutics, today announced that the U.S. Food and Drug [...]
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29/04/2026
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expected to Begin Patient [...]
GH Research Announces Pricing of $117.5 Million Underwritten Offering
29/04/2026
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]

Pages